Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients

Pacheco, Larissa Sgaria; Garcı́a, Valter Duro; Prá, Ronivan Luis Dal; Cardoso, Bruna Doleys; Rodrigues, Mariana Ferras; Zanetti, Helen Kris; Meinerz, Gisele; Neumann, Jorge; Gnatta, Diego; Keitel, Elizete

doi:10.1590/2175-8239-jbn-3860

Cited by 2 publications

(2 citation statements)

References 23 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is no clear evidence of an association between the kind of antirejection therapy and HCV activity in kidney transplant recipients. Some reports suggest a potential benefit of mTOR inhibitors in controlling viral replication (58–60), but this therapeutic approach should be weighed against the increased risk of acute rejections and the poor tolerability of these agents (61).…”

Section: Hcv Infection In Kidney Transplant Recipientsmentioning

confidence: 99%

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents

Angeletti¹,

Cantarelli

Cravedi

2019

Front. Med.

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a systemic disorder that frequently associates with extrahepatic manifestations, including nephropathies. Cryoglobulinemia is a typical extrahepatic manifestation of HCV infection that often involves kidneys with a histological pattern of membranoproliferative glomerulonephritis. Other, less common renal diseases related to HCV infection include membranous nephropathy, focal segmental glomerulosclerosis, IgA nephropathy, fibrillary and immunotactoid glomerulopathy. Over the last decades, the advent of direct-acting antiviral therapies has revolutionized treatment of HCV infection, dramatically increasing the rates of viral clearance. In patients where antiviral therapy alone fails to induce renal disease remission add-on B-cell depleting agents represent an alternative to counteract the synthesis of pathogenic antibodies. Immunosuppressive therapies, such as steroids, alkylating agents, and plasma exchanges, may still represent an effective option to inhibit immune-complex driven inflammatory response, but the potentially associated increase of HCV replication and worsening of liver disease represent a serious limitation to their use.

show abstract

Section: Hcv Infection In Kidney Transplant Recipientsmentioning

confidence: 99%

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents

Angeletti¹,

Cantarelli

Cravedi

2019

Front. Med.

View full text Add to dashboard Cite

show abstract

“…There is no conclusive proof that anti-rejection treatment type and HCV activity in kidney transplant recipients are related. A study suggested that mTOR inhibitors may help reduce viral replication [ 88 ]. A balance between decreasing the viral load, drug side effects, and the increased risk of acute rejections should be considered [ 89 ].…”

Section: Reviewmentioning

confidence: 99%

Hepatitis Virus C-associated Nephropathy: A Review and Update

Habas¹,

Farfar²,

Errayes³

et al. 2022

Cureus

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection causes hepatic and extrahepatic organ involvement. Chronic kidney disease (CKD) is a prevalent non-communicable disorder, accounting for significant morbidity and mortality worldwide. Acute kidney injury and CKD are not uncommon sequels of acute or chronic HCV infection.The pathogenesis of HCV-associated kidney injuries is not well explored. Excess cryoglobulin production occurs in HCV infection. The cryoglobulin may initiate immune complex-mediated vasculitis, inducing vascular thrombosis and inflammation due to cryoglobulin deposits. Furthermore, direct damage to nephron parts also occurs in HCV patients. Other contributory causes such as hypertension, diabetes, and genetic polymorphism enhance the risk of kidney damage in HCV-infected individuals. Implementing CKD prevention, regular evaluation, and therapy may improve the HCV burden of kidney damage and its related outcomes. Therefore, in this review, we discuss and update the possible mechanism(s) of kidney injury pathogenesis with HCV infection. We searched for related published articles in EMBASE, Google Scholar, Google, PubMed, and Scopus. We used various texts and phrases, including hepatitis virus and kidney, HCV and CKD, kidney pathology in viral hepatitis, kidney transplantation in HCV-infected patients, kidney allograft survival in viral hepatitis patients, mechanism of kidney pathology in viral hepatitis, dialysis and viral hepatitis, HCV infection and kidney injuries, and viral hepatitis and CKD progression, etc. to identify relevant articles.

show abstract

Effect of conversion from calcineurin inhibitors to everolimus on hepatitis C viremia in adult kidney transplant recipients

Cited by 2 publications

References 23 publications

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents

Hepatitis Virus C-associated Nephropathy: A Review and Update

Contact Info

Product

Resources

About